Zentalis Pharmaceuticals Llc

Price Chart

Risk-Adjusted Performance

Zentalis Pharmaceuticals Llc (ZNTL) Price Performance

Zentalis Pharmaceuticals Llc (ZNTL) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $2.47, down 5.73% from the previous close.

Over the past year, ZNTL has traded between a low of $1.04 and a high of $3.74. The stock has gained 40.3% over this period. It is currently 34.0% below its 52-week high.

Zentalis Pharmaceuticals Llc has a market capitalization of $169.65M.

About Zentalis Pharmaceuticals Llc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.